NCT03463265 - Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

August 26, 2022

Study Completion Date

August 26, 2022

Conditions

High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma

Interventions

DRUG

nab-sirolimus

nab-sirolimus, single agent

DRUG

nab-sirolimus + temozolomide

temozolomide, combination

DRUG

nab-sirolimus + bevacizumab

bevacizumab, combination

DRUG

nab-sirolimus + lomustine

lomustine, combination

DRUG

nab-sirolimus + marizomib (MRZ)

marizomib (MRZ), combination

DRUG

nab-sirolimus + temozolomide + radiotherapy

temozolomide + radiotherapy, combination

Trial Locations (3)

John Wayne Cancer Institute, Santa Monica

Hoag Memorial Hospital Presbyterian, Newport Beach

St. Joseph Heritage Healthcare, Fullerton